key: cord-0320454-l5r21v8v
authors: Puhl, Ana C.; Fernandes, Rafaela S.; Godoy, Andre S.; Gil, Laura H. V. G.; Oliva, Glaucius; Ekins, Sean
title: Discovery of a Novel Inhibitor for Chikungunya Virus
date: 2022-03-24
journal: bioRxiv
DOI: 10.1101/2022.03.23.485574
sha: e051f3f6f0d5bcaed7ce5907d137f61c29e7b09f
doc_id: 320454
cord_uid: l5r21v8v

Chikungunya virus (CHIKV) is the etiological agent of chikungunya fever, a (re)emerging arbovirus infection, that causes severe and often persistent arthritis, representing a serious health problem worldwide for which no antivirals are currently available. Despite the efforts over the last decade to identify and optimize new inhibitors or to reposition existing drugs, no compound has progressed to clinical trials and prophylaxis is based on vector control, which has shown limited success in containing the virus. Herein, we screened 36 compounds using a replicon system and ultimately identified 3-methyltoxoflavin with activity against CHIKV using cell assays (EC50 200 nM). We have additionally screened 3-methyltoxoflavin against a panel of viruses and showed that it also inhibits yellow fever virus (IC50 370 nM, SI=3.2 in Huh-7 cells). 3-methyltoxoflavin is a known protein disulfide isomerase (PDI) inhibitor, and inhibitor of alphaviruses which likely depends on this host protein to aid in facilitating disulfide bond formation and isomerization, since alphaviruses require conserved cysteine residues for proper folding and assembly of the E1 and E2 envelope glycoproteins. In summary we demonstrate that 3-methyltoxoflavin has activity against CHIKV and may represent a starting point for optimization to develop inhibitors to this and other viruses.

with Renilla luciferase Assay Reagent (100 μl) (Promega). GLuc activity was measured 113

using SpectraMax i3 Multi-mode Detection Platform (Molecular Devices). 114

Compounds that inhibited GLuc activity in ≥ 80% were assayed for the 115 determination of their effective (EC 50 ) and cytotoxicity (CC 50 ) concentrations. As 116 described above, replicon cells were seeded in 96-well plates and after 16 h of 117 incubation at 37 °C 5% CO 2 , medium was replaced with fresh DMEM with 2% FBS and 118 compounds at 2-fold serial dilutions were added to the cells. After a 48 h-incubation, 40 119 µL of the cells' supernatant were mixed with Renilla luciferase Assay Reagent (100 μL) 120 (Promega) and Gluc activity were measured using SpectraMax i3 Multi-mode Detection 121

Platform (Molecular Devices). The compounds concentrations required to inhibit 50% of 122 the Gluc activity (EC 50 ) were calculated using the OriginPro 9.0 software. BHK-21 cells 123 in 1% DMSO were used as negative control. 124

The cytotoxicity of compounds were evaluated by a cell proliferation-based MTT 125

(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 20 . Replicon cells 126

were seeded in 96-well plates as described above. After 48 h of incubation with the 127 compounds at 2-fold serial dilutions, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-128 diphenyltetrazolium bromide) solution (5mg/mL in PBS) was added to the wells at one 129 tenth of the well volume and the plates were incubated at 37 ºC 5% CO 2 for 3-4 hours. 130

Next, the medium was removed, and formazan crystals were solubilized in DMSO. 131 Absorbance was measured at 570 nm wavelength in SpectraMax 384 plate reader 132 (Molecular Devices). The compounds concentrations required to cause 50% cytotoxicity 133 (CC 50 ) were estimated using the OriginPro 9.0 software. All the antiviral assays were 134 performed twice in duplicates. 135 136

The cell proliferation-based MTT was also used to evaluate the potential drug-138 induced hepatotoxicity of compound 3-methyltoxoflavin using hepatocellular carcinoma 139 cells (HepG2). Approximately 2 x 10 4 HepG2 cells per well were seeded in 96-well 140 plates and the assay was performed as described above. The compound concentration 141 required to cause 50% cytotoxicity (CC 50 ) was estimated using the OriginPro 9.0 142 software. The assay was performed twice in duplicates. (Table S1 ). The assays were conducted as 151 described 21 . Two sets of data are provided: (1) EC 50 , CC 50 , and SI 50 obtained from the 152 neutral red assay, and (2) EC 90 (obtained from the VYR assay), CC 50 (same value as for 153 item 1), and SI 90 . 154

For the replicon-based assays, statistical calculations of Z′-values were made as follows: Z′ We screened 36 compounds (Table 1) (Table 1) . Nine compounds inhibited the luciferase activity (furaltadone, 174 amodiaquine, promazine, fluphenazine, quinacrine, 4-hydroxyderricin, xanthoangelol, 175 (2E)-1-[3-(2-Hydroperoxy-3-methyl-3-buten-1-yl)-2-hydroxy-4-methoxyphenyl]-3-(4-176 hydroxyphenyl)-2-propen-1-one, 3-methyltoxoflavin) in ≥ 80% and were further assayed 177 for the determination of their EC 50 and CC 50 values. These compounds were tested in a 178 dose-dependent manner, and only xanthoangelol, quinacrine and 3-methyltoxoflavin 179 showed activity. Xanthoangelol and quinacrine decreased the GLuc signals in a dose-180 dependent manner, with EC 50 values in the low micromolar range (Figure 1 A,B) . Those 181 compounds exhibited high cytotoxicity to the replicon cells, resulting in poor selectivity 182 indexes (CC 50 /EC 50 , SI)) of 1.66 and 1.64, respectively ( Figure 1A ,B). In contrast, 3-183 methyltoxoflavin exhibited a low cytotoxicity to the cells with an EC 50 of 20 ± 0.04 µM 184 and SI=30.8 ( Figure 1C ). We also evaluated 3-methyltoxoflavin hepatotoxicity using 185

HepG2 cells, which resulted in a CC 50 of 11.0 ± 1.73 µM ( Figure 1D ), showing that this 186 compound displays a moderate to low toxicity to human liver cells. 3-methyltoxoflavin is 187 a protein disulfide isomerase (PDI) inhibitor 25 . 188

Alphaviruses require conserved cysteine residues for proper folding and 189 assembly of the E1 and E2 envelope glycoproteins 26 , and likely depends on host PDI to 190 aid in facilitating disulfide bond formation and isomerization in these proteins. 3-191

Methyltoxoflavin is a potent PDI inhibitor, with an IC 50 of 170 nM 25 and we hypothesize 192 that the mechanism for the activity of 3-methyltoxoflavin may be due in part to inhibition 193 of PDI 25 . PDI is a promising target for cancer therapy 25, 27 and many viruses, such as 194 HIV 28 , CHIKV 29 , Dengue 30, 31 , Zika 31 , Hepatitis C 32 , influenza 33 , as well as others 34 . We have demonstrated that 3-methyltoxoflavin has activity against CHIKV and was also 212 screened a panel of viruses (Table S1) , and only showed activity against yellow fever 213 (YFV 17D strain) with an EC 50 0.37 µM and SI 3.2 in the visual cytopathic toxicity assay 214 (Table 2) . CHIKV and YFV are both arboviruses transmitted by the Aedes aegypti 215 mosquito, however CHIKV belongs to the family Togaviridae and YFV belongs to the 216

Flaviviridae. The mechanism of action remains to be fully elucidated but it may suggest 217 that 3-methyltoxoflavin could be further optimized to develop novel therapeutic agents to 218 treat these viruses. 219 220

Acknowledgments 221

We kindly acknowledge Dr. Mindy Davis and colleagues for assistance with antiviral 222 testing services through NIAID and our colleagues at Collaborations Pharmaceuticals, 223

Inc. for their assistance in the early stages of this project. We kindly acknowledge Dr. 

Oliva 2 and Sean Ekins 1#

840 Main Campus Drive

3 Department of Virology, Oswaldo Cruz Foundation

Moraes Rego, s/n -Cidade Universitária

Email: ana@collaborationspharma.com; sean@collaborationspharma